PuSH - Publikationsserver des Helmholtz Zentrums München

Protzer, U. ; Abken, H.*

Can engineered 'Designer' T cells outsmart chronic hepatitis B?

Hepat. Res. Treat. 2010:901216 (2010)
Verlagsversion DOI
Free by publisher
Creative Commons Lizenzvertrag
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
More than 350 million people worldwide are persistently infected with human heptatitis B virus (HBV) and at risk to develop liver cirrhosis and hepatocellular carcinoma making long-term treatment necessary. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Recent efforts in adoptive cell therapy are experimentally exploring immunotherapeutic elimination of HBV-infected cells by means of a biological attack with genetically engineered "Designer" T cells.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
ISSN (print) / ISBN 2090-1364
e-ISSN 2090-1372
Quellenangaben Band: 2010, Heft: , Seiten: , Artikelnummer: 901216 Supplement: ,
Verlag Hindawi
Begutachtungsstatus Peer reviewed